To include your compound in the COVID-19 Resource Center, submit it here.

With Celgene's $13.4B sale of Otezla, Amgen adds to anti-inflammatory franchise

Investors appeared to be more than satisfied with Celgene's take from the sale of Otezla to Amgen for $13.4 billion in cash, removing a hurdle from BMS's path toward the completion of its proposed $74 billion acquisition of Celgene.

Shares of Bristol-Myers Squibb Co. (NYSE:BMY) rose about 3%, adding $2.5 billion to its market cap Monday. The pharma said in June that following discussions with the Federal Trade Commission, it would divest Otezla

Read the full 721 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE